Russell Investments Group Ltd. reduced its holdings in Encompass Health Co. (NYSE:EHC – Get Rating) by 11.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 343,631 shares of the company’s stock after selling 44,632 shares during the quarter. Russell Investments Group Ltd. owned about 0.34% of Encompass Health worth $15,539,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Sei Investments Co. lifted its stake in shares of Encompass Health by 29.4% in the 2nd quarter. Sei Investments Co. now owns 213,253 shares of the company’s stock valued at $12,010,000 after purchasing an additional 48,456 shares during the period. Mackenzie Financial Corp purchased a new position in shares of Encompass Health in the 2nd quarter valued at approximately $289,000. Mitsubishi UFJ Trust & Banking Corp lifted its stake in shares of Encompass Health by 12.4% in the 2nd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 8,996 shares of the company’s stock valued at $504,000 after purchasing an additional 995 shares during the period. Aptus Capital Advisors LLC purchased a new position in shares of Encompass Health in the 3rd quarter valued at approximately $1,788,000. Finally, 1492 Capital Management LLC purchased a new position in shares of Encompass Health in the 2nd quarter valued at approximately $221,000. 96.14% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In related news, Director Greg D. Carmichael bought 1,830 shares of the stock in a transaction on Monday, October 31st. The stock was bought at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the acquisition, the director now directly owns 10,546 shares in the company, valued at $576,549.82. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.70% of the stock is owned by company insiders.
Encompass Health Trading Down 0.7 %
EHC opened at $61.39 on Friday. The stock has a market cap of $6.13 billion, a price-to-earnings ratio of 22.57, a P/E/G ratio of 2.61 and a beta of 1.03. The stock’s 50 day moving average price is $59.01 and its 200-day moving average price is $53.68. Encompass Health Co. has a one year low of $44.33 and a one year high of $74.61. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.21 and a current ratio of 1.21.
Encompass Health (NYSE:EHC – Get Rating) last posted its earnings results on Wednesday, October 26th. The company reported $0.67 earnings per share for the quarter, missing analysts’ consensus estimates of $0.68 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Encompass Health had a return on equity of 15.59% and a net margin of 5.39%. On average, equities analysts forecast that Encompass Health Co. will post 2.79 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms have recently commented on EHC. Stephens lowered their target price on Encompass Health from $60.00 to $58.00 and set an “overweight” rating for the company in a research note on Friday, October 28th. Raymond James lifted their price objective on Encompass Health from $65.00 to $72.00 and gave the company a “strong-buy” rating in a research note on Friday, October 28th. TheStreet upgraded Encompass Health from a “c+” rating to a “b-” rating in a research note on Wednesday, December 21st. Finally, StockNews.com initiated coverage on Encompass Health in a research note on Wednesday, October 12th. They set a “hold” rating for the company. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Encompass Health currently has a consensus rating of “Buy” and a consensus target price of $64.13.
About Encompass Health
Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through the Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitative treatment and care to patients who are recovering from stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions and amputations.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Encompass Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Encompass Health wasn’t on the list.
While Encompass Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.